ProTarget results presented at ESMO, 2025
ProTarget participated in this year’s ESMO Congress with a poster presentation, sharing results from the first 301 patients enrolled in the trial.
ProTarget participated in this year’s ESMO Congress, held in Berlin, Germany, with a poster presentation sharing results from the first 301 patients enrolled in the trial — an important milestone that we have been looking forward to!
ProTarget is a Danish national precision oncology trial investigating the efficacy and safety of EMA-approved targeted cancer therapies when used outside their current indications. The trial includes patients with advanced and treatment-refractory cancer and actionable genomic alterations matched to relevant targeted drugs by the Danish National Molecular Tumor Board (DNMTB).
Based on this nationwide and cross-disciplinary effort, the study presented the key finding that a subgroup of patients demonstrates clinical benefit from treatment with a targeted drug matching the genomic alterations driving their cancer.
This result is particularly meaningful because ProTarget patients have exhausted all standard treatment options available before entering the study. Finding that some patients in this setting benefit from targeted treatments currently not available to them, suggests that there is a significant untapped potential among already approved targeted drugs – therapies that our clinicians know well and use daily in other cancer types.
“Behind every data point is a patient who has exhausted all standard treatment options. The fact that we see this CBR in a late-stage population and outside labelled indications highlights the value of molecular profiling and the strength of our collaborative precision oncology setup across Denmark,” says Tina Kringelbach, Trial Project Leader of the ProTarget trial.
From August 2020 to December 2024, more than 6,600 genomic reports were reviewed by the DNMTB (including repeat biopsies and reevaluations). In total, 301 patients initiated treatment across 8 clinical sites in Denmark, representing 47% of pts. with a DNMTB-confirmed drug-variant-match, and screen failure rates were as low as 15%.
“ProTarget demonstrates what is possible when we combine nationwide collaboration, molecular diagnostics, and clinical expertise. The Danish cancer research infrastructure allows us to translate genomic data into new treatment opportunities for patients who otherwise have no options left,” says Professor Ulrik Lassen, MD, Study Principal Investigator and Sponsor of the ProTarget study.
Next step is to publish both positive and negative results from the trial and dive into translational analyses that will provide us with new insight and knowledge to improve patient selection for these drugs and reveal molecular mechanisms of drug resistance.
ProTarget continues to enroll patients and expand treatment arms. The trial represents an important step forward towards more individualized cancer treatment in Denmark.
Thanks to all patients and families for your trust and participation and thanks to all colleagues, collaborators and supporters, your efforts and contributions made this journey possible.
